(i) FOXE1

Forkhead box E1 (FOXE1) is a single exon gene located at chromosome 9q22·33 encoding the transcription factor FOXE1 (or TTF-2), which likely plays a crucial role in thyroid morphogenesis. This transcription factor regulates thyroglobulin and thyroid peroxidase expression. Many association studies have been performed to investigate the role of FOXE1 polymorphisms in TC susceptibility. Several variants of this gene have been positively correlated with thyroid malignancy (Table S1). However, two common variations (rs1867277 and rs71369530) have been associated with TC risk in various ethnic groups (Matsuse et al., Reference Matsuse, Takahashi, Mitsutake, Nishihara, Hirokawa, Kawaguchi, Rogounovitch, Saenko, Bychkov, Suzuki, Matsuo, Tajima, Miyauchi, Yamada, Matsuda and Yamashita2011; Gudmundsson et al., Reference Gudmundsson, Sulem, Gudbjartsson, Jonasson, Masson, He, Jonasdottir, Sigurdsson, Stacey, Johannsdottir, Helgadottir, Li, Nagy, Ringel, Kloos, de Visser, Plantinga, den Heijer, Aguillo, Panadero, Prats, Garcia-Castaño, De Juan, Rivera, Walters, Bjarnason, Tryggvadottir, Eyjolfsson, Bjornsdottir, Holm, Olafsson, Kristjansson, Kristvinsson, Magnusson, Thorleifsson, Gulcher, Kong, Kiemeney, Jonsson, Hjartarson, Mayordomo, Netea-Maier, de la Chapelle, Hrafnkelsson, Thorsteinsdottir, Rafnar and Stefansson2012; Jones et al., Reference Jones, Howarth, Martin, Gorman, Mihai, Moss, Auton, Lemon, Mehanna, Mohan, Clarke, Wadsley, Macias, Coatesworth, Beasley, Roques, Martin, Ryan, Gerrard, Power, Bremmer, Tomlinson and Carvajal-Carmona2012).

The SNP rs1867277 is caused by an A/G transition in the 5′-UTR region of the gene, whereas the rs71369530 polymorphism is a polymorphic polyalanine tract (rs71369530, polyAla) just distal to its DNA-binding domain. Recently, it has been shown that the variant rs1867277 affects FOXE1 transcription. In fact, it has been reported that the A allele of this SNP increases the transcriptional activity of the FOXE1 gene promoter, by the recruitment of leucine zipper upstream stimulatory factors 1 and 2 (Landa et al., Reference Landa, Ruiz-Llorente, Montero-Conde, Inglada-Pérez, Schiavi, Leskelä, Pita, Milne, Maravall, Ramos, Andía, Rodríguez-Poyo, Jara-Albarrán, Meoro, del Peso, Arribas, Iglesias, Caballero, Serrano, Picó, Pomares, Giménez, López-Mondéjar, Castello, Merante-Boschin, Pelizzo, Mauricio, Opocher, Rodríguez-Antona, González-Neira, Matías-Guiu, Santisteban and Robledo2009). Regarding the FOXE1 polyAla tract, it has been reported that it has 11–22 alanine residues, although FOXE1 14Ala and FOXE1 16Ala account for greater than 98% of reported alleles (Kallel et al., Reference Kallel, Belguith-Maalej, Akdi, Mnif, Charfeddine, Galofré, Ghorbel, Abid, Marcos, Ayadi, Velázquez and Hadj Kacem2010). Some studies have suggested a functional consequence for the presence of polyAla expansions (>14) but not for contractions (⩽14). FOXE1 with 16Ala induced a stronger transactivation of the thyroglobulin promoter than the 14Ala variant (Carré et al., Reference Carré, Castanet, Sura-Trueba, Szinnai, Van Vliet, Trochet, Amiel, Léger, Czernichow, Scotet and Polak2007). However, a recent study has reported a modest transcriptional impairment of 16Ala FOXE1, when compared with the function of the 14Ala variant, on FOXE1 responsive promoters, which was not attributable to differences in DNA binding (Liyanarachchi et al., Reference Liyanarachchi, Wojcicka, Li, Czetwertynska, Stachlewska, Nagy, Hoag, Wen, Ploski, Ringel, Kozłowicz-Gudzinska, Gierlikowski, Jazdzewski, He and de la Chapelle2013).

(ii) RET

The rearranged during transfection (RET) proto-oncogene is one of the receptor tyrosine kinase, cell-surface molecules that transduce signals for cell growth and differentiation. A wide panel of SNPs in the RET gene have been reported to the curated databases but only a limited, and perhaps selected, number of these RET variants have been tested for an association (Table S1). Among them are the nonsynonymous variant G691S (rs1799939) in exon 11, the synonymous variants L769L (rs1800861) in exon 13, S836S (rs1800862) in exon 14 and S904S (rs1800863) in exon 15. These SNPs have been repeatedly implicated in the increase of MTC risk (Figlioli et al., Reference Figlioli, Landi, Romei, Elisei and Gemignani2013; Lantieri et al., Reference Lantieri, Caroli, Ceccherini and Griseri2013). However, the effect of RET polymorphisms on other types of TC remains unclarified. Only the SNP S836S was positively correlated with PTC but not with FTC. Despite the presence of some studies suggesting a possible role of the RET polymorphisms in MTC susceptibility, the data about the true association between MTC and RET variants were conflicting and extremely variable. The cause of this incoherence has been assigned to the limited number of patients enrolled (underpowered studies) and/or to the genetic variability among different populations (Weber & Eng, Reference Weber and Eng2005; Fugazzola et al., Reference Fugazzola, Muzza, Mian, Cordella, Barollo, Alberti, Cirello, Dazzi, Girelli, Opocher, Beck-Peccoz and Persani2008). To avoid this high discrepancy in observed data, Weber & Eng (Reference Weber and Eng2005) in their study have suggested the application of rigorous parameters to dissect out the few true RET modifiers among a vast amount of random associations and proposed an approach termed reverse phenotyping. Here, the genotype/haplotype is identified in a cohort study and then associated with phenotypical factors, analogous to an unsupervised analysis used in global gene expression analysis that avoids assumptions based on the phenotype to identify hidden patterns.

On the other hand, it has been shown that a synonymous polymorphism in exon 2 (Ala45Ala, rs1800858), which occurred at a lower frequency among cases of MTC, may confer a protective allele against the development of MTC (Cebrian et al., Reference Cebrian, Lesueur, Martin, Leyland, Ahmed, Luccarini, Smith, Luben, Whittaker, Pharoah, Dunning and Ponder2005). However, a recent study has shown that the G allele of this SNP remarkably increases the risk of TC (Huang & Yang, Reference Huang and Yang2015). The mechanism by which the silent polymorphisms may act in the development of TC may include transcript stability, mRNA structure, and DNA protein binding and protein folding (Ho et al., Reference Ho, Li, Zhao, Wei and Sturgis2005). In the case of the nonsynonymous SNP G691S, the two amino acids, glycine in the wild-type RET protein and serine in the polymorphic RET variant, confer different electrochemical and conformational structures to the RET protein, and consequently influence the processing, folding, subcellular localization or function of the protein (Robledo et al., Reference Robledo, Gil, Pollán, Cebrián, Ruíz, Azañedo, Benitez, Menárguez and Rojas2003). More recently, the functional activity of this variant has been investigated by western blot analyses and the result has showed that the fraction of Ret9-G691S protein located at the plasma membrane level was overrepresented when compared to Ret9-WT, suggesting facilitated targeting at the cell membrane for this variant (Fugazzola et al., Reference Fugazzola, Muzza, Mian, Cordella, Barollo, Alberti, Cirello, Dazzi, Girelli, Opocher, Beck-Peccoz and Persani2008).

The relationship between the RET variants and the clinicopathological features of the disease is, yet, unclarified. In the study of Ceolin et al. (Reference Ceolin, Siqueira, Ferreira, Romitti, Maia, Leiria, Crispim, Ashton-Prolla and Maia2012), no significant correlation has been observed between the RET variants analysed (G691S, L769L, S836S and S904S) and the clinicopathological parameters of the patients. Nevertheless, patients carrying haplotypes with three or four risk alleles had increased risk for lymph node and distant metastases at diagnosis. More recently, two RET SNPs (G691S and S904S) have been significantly associated with an increase in tumour size at diagnosis and a more aggressive disease (Santos et al., Reference Santos, Azevedo, Martins, Rodrigues and Lemos2014).

(iii) XRCC1

The X-ray repair cross complementing group 1 (XRCC1) gene encodes a scaffold protein involved in the repair of DNA single-strand breaks formed by ionizing radiation and alkylation damage. Numerous validated SNPs in the XRCC1 gene have been identified, only three of which were most widely investigated including Arg194Trp on exon 6 (rs1799782, C/T), Arg280His on exon 9 (rs25489, G/A) and Arg399Gln on exon 10 (rs25487, G/A; Table S1). Over the last decade, several epidemiological studies have reported the association regarding XRCC1 polymorphisms and TC risk (Fard-Esfahani et al., Reference Fard-Esfahani, Fard-Esfahani, Fayaz, Ghanbarzadeh, Saidi, Mohabati, Bidoki and Majdi2011; Ryu et al., Reference Ryu, Tae, Min, Jeong, Cho, Lee and Ahn2011; Santos et al., Reference Santos, Branco, Silva, Azevedo, Gil, Manita, Ferreira, Limbert, Rueff and Gaspar2012). However, a significant heterogeneity among studies has been observed. In fact, increased risks for DTC have been shown for Arg194Trp and Arg280His genotypes while a mild reduction of risk has been estimated for the Arg399Gln polymorphism (Fard-Esfahani et al., Reference Fard-Esfahani, Fard-Esfahani, Fayaz, Ghanbarzadeh, Saidi, Mohabati, Bidoki and Majdi2011). Nevertheless, it has been suggested in a meta-analysis involving eight different populations that the Arg399Gln polymorphism may be associated with decreased TC risk among the Caucasian population while the Arg194Trp SNP may be associated with a tendency of increased TC risk in the two larger sample size trials. But, no significant association has been found between the Arg280His polymorphism and TC (Qian et al., Reference Qian, Liu, Xu, Chen, Chen, Yi, Zhou and Tang2012). On the other hand, in a more recent study only the Arg194Trp SNP has been associated with increased risk of TC (Wang et al., Reference Wang, Zhang, Liu, Liu and Wang2015).

It has been suggested that the functional significance of the Arg194Trp polymorphism is due to its location in an evolutionarily conserved region, and the occurrence of chromosomal breaks is largely increased among cases with the Arg/Arg genotype (Vodicka et al., Reference Vodicka, Stetina, Polakova, Tulupova, Naccarati, Vodickova, Kumar, Hanova, Pardini, Slyskova, Musak, De Palma, Soucek and Hemminki2007). For the Arg399Gln polymorphism, which is located within a relatively nonconserved region between conserved residues of the BRCA1 COOH terminus domain, it may be associated with higher sister chromatid exchange frequency and prolonged cell cycle delay in response to ionizing radiation (Hu et al., Reference Hu, Smith, Miller, Mohrenweiser, Golden and Case2001; Matullo et al., Reference Matullo, Dunning, Guarrera, Baynes, Polidoro, Garte, Autrup, Malaveille, Peluso, Airoldi, Veglia, Gormally, Hoek, Krzyzanowski, Overvad, Raaschou-Nielsen, Clavel-Chapelon, Linseisen, Boeing, Trichopoulou, Palli, Krogh, Tumino, Panico, Bueno-De-Mesquita, Peeters, Lund, Pera, Martinez, Dorronsoro, Barricarte, Tormo, Quiros, Day, Key, Saracci, Kaaks, Riboli and Vineis2006). Although in the same gene, these two different SNPs may exert influence on the XRCC1 activity in different ways, thus they might have different effects on cancer risk. Regarding the Arg280His polymorphism, which is located in the PCNA-binding region of the XRCC1 protein, it has been suggested that this variant could potentially alter the structure of XRCC1 and its ability to interact with apurinic/apyrimidinic endonuclease (Yan et al., Reference Yan, Yanan, Donglan, Na, Rongmiao and Zhifeng2009).

(iv) Other genomic regions

(b) Near FOXE1 (9q22·33)

Since it has been shown that the SNP rs965513 (located 57 kb upstream of the FOXE1 gene on chromosome 9q22) was a new hot spot for TC susceptibility (Gudmundsson et al., Reference Gudmundsson, Sulem, Gudbjartsson, Jonasson, Sigurdsson, Bergthorsson, He, Blondal, Geller, Jakobsdottir, Magnusdottir, Matthiasdottir, Stacey, Skarphedinsson, Helgadottir, Li, Nagy, Aguillo, Faure, Prats, Saez, Martinez, Eyjolfsson, Bjornsdottir, Holm, Kristjansson, Frigge, Kristvinsson, Gulcher, Jonsson, Rafnar, Hjartarsson, Mayordomo, de la Chapelle, Hrafnkelsson, Thorsteinsdottir, Kong and Stefansson2009; Reference Gudmundsson, Sulem, Gudbjartsson, Jonasson, Masson, He, Jonasdottir, Sigurdsson, Stacey, Johannsdottir, Helgadottir, Li, Nagy, Ringel, Kloos, de Visser, Plantinga, den Heijer, Aguillo, Panadero, Prats, Garcia-Castaño, De Juan, Rivera, Walters, Bjarnason, Tryggvadottir, Eyjolfsson, Bjornsdottir, Holm, Olafsson, Kristjansson, Kristvinsson, Magnusson, Thorleifsson, Gulcher, Kong, Kiemeney, Jonsson, Hjartarson, Mayordomo, Netea-Maier, de la Chapelle, Hrafnkelsson, Thorsteinsdottir, Rafnar and Stefansson2012), the relationship between this polymorphic site and TC risk has been independently replicated by subsequent studies (Wang et al., Reference Wang, Feng, Guo, Wei, Li, Wang, Wang, Wang, Ma, Jin, Ji and Wang2013). It has been suggested to tag a functional variation near the FOXE1 gene that contributes to an increased risk of developing TC. Besides, the variant has also been associated with low serum concentrations of thyroid stimulating hormone, and free thyroxin (Gudmundsson et al., Reference Gudmundsson, Sulem, Gudbjartsson, Jonasson, Masson, He, Jonasdottir, Sigurdsson, Stacey, Johannsdottir, Helgadottir, Li, Nagy, Ringel, Kloos, de Visser, Plantinga, den Heijer, Aguillo, Panadero, Prats, Garcia-Castaño, De Juan, Rivera, Walters, Bjarnason, Tryggvadottir, Eyjolfsson, Bjornsdottir, Holm, Olafsson, Kristjansson, Kristvinsson, Magnusson, Thorleifsson, Gulcher, Kong, Kiemeney, Jonsson, Hjartarson, Mayordomo, Netea-Maier, de la Chapelle, Hrafnkelsson, Thorsteinsdottir, Rafnar and Stefansson2012). More recently, a significant correlation has been observed between this polymorphic site and more aggressive disease (advanced stage) (Penna-Martinez et al., Reference Penna-Martinez, Epp, Kahles, Ramos-Lopez, Hinsch, Hansmann, Selkinski, Grünwald, Holzer, Bechstein, Zeuzem, Vorländer and Badenhoop2014)

(i) BRAF

The BRAF proto-oncogene, a serine/threonine kinase, encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signalling pathway, which affects cell division, differentiation and secretion. Mutations in this gene are the most common genetic event in PTC. About 40 mutations have been identified in human thyroid tumours (COSMIC database, 2015) most of which are missense substitutions (36·8%). Most oncogenic BRAF mutations are located in the glycine-rich P loop (residues 462–471) and activation segment (residues 593–622) (Wan et al., Reference Wan, Garnett, Roe, Lee, Niculescu-Duvaz, Good, Jones, Marshall, Springer, Barford and Marais2004; Michaloglou et al., Reference Michaloglou, Vredeveld, Mooi and Peeper2008).

The Glu586Lys, Val600Glu, Val600Asp, Val600Lys, Val600Arg and Lys601Glu mutations have been classified as a high kinase activity group, while nine other mutations, Gly464Glu, Gly464Val, Gly466Ala, Gly469Glu, Asn581Ser, Phe595Leu, Leu597Val, Leu597Arg and Thr599Ile, have been classified as an intermediate kinase activity group. However, four mutations, Gly466Glu, Gly466Val, Gly596Arg and Asp594Val, have lower kinase activity than basal wild-type BRAF activity (Wan et al., Reference Wan, Garnett, Roe, Lee, Niculescu-Duvaz, Good, Jones, Marshall, Springer, Barford and Marais2004; Michaloglou et al., Reference Michaloglou, Vredeveld, Mooi and Peeper2008). The BRAF Val600 mutations mimic phosphorylation of Thr599/Ser602 (required for the activation of wild-type BRAF) and destabilize interactions between residues within the hydrogen bond network in BRAF, rendering the BRAF constitutively active (Michaloglou et al., Reference Michaloglou, Vredeveld, Mooi and Peeper2008; Fratev & Jonsdottir, Reference Fratev and Jonsdottir2009).

Over 90% of BRAF mutations are T1799A, resulting in a substitution of glutamine for valine at amino acid codon 600 (Val600Glu, BRAF ^V600E), while other BRAF mutations are rarely reported. It has been shown that BRAF ^V600E leads to expression of a constitutively active kinase BRAF and was associated with aggressive clinicopathological characteristics (such as extrathyroidal invasion, lymph node metastasis and advanced tumour stage) (Lee et al., Reference Lee, Gao, Ji, Yu, Feng, Li, Zhang, Cheng and Zhao2009; Lin et al., Reference Lin, Wang, Zhang, Dai, Hu and Qu2010), high tumour recurrence even with low stage disease (Xing et al., Reference Xing, Westra, Tufano, Cohen, Rosenbaum, Rhoden, Carson, Vasko, Larin, Tallini, Tolaney, Holt, Hui, Umbricht, Basaria, Ewertz, Tufaro, Califano, Ringel, Zeiger, Sidransky and Ladenson2005) as well as radioiodine treatment failure in PTC (Mian et al., Reference Mian, Barollo, Pennelli, Pavan, Rugge, Pelizzo, Mazzarotto, Casara, Nacamulli, Mantero, Opocher, Busnardo and Girelli2008) and high tumour related mortality (Elisei et al., Reference Elisei, Ugolini, Viola, Lupi, Biagini, Giannini, Romei, Miccoli, Pinchera and Basolo2008). More recently, the BRAF ^V600E mutation has been investigated in a large cohort of PTC and it has been suggested that this genetic alteration represents a diverse group of tumours, consisting of at least four molecular subtypes, with variable degrees of thyroid differentiation. In this study, BRAF ^V600E has been associated with less-differentiated tumours enriched for classical and tall cell histology, and with distinct gene expression and DNA methylation patterns (Cancer Genome Atlas Research Network, 2014).

BRAF fusions have been identified in PTC (2·7%) with diverse gene patterns including SND1 (0·6%) and MKRN1 (0·2%). Some of these fusions supported BRAF signalling with expression and conservation of its kinase domain (MKRN1/BRAF), while others suggested an alternative activating mechanism (Cancer Genome Atlas Research Network, 2014).

(ii) RET

The RET proto-oncogene has been involved in the oncogenesis of medullary and papillary thyroid carcinomas by activation of tyrosine kinases either by point mutation or rearrangement.

There are now at least 30 types of RET/PTC rearrangements involving RET and 10 different genes. RET/PTC1 (fusion CCDC6 and RET) and RET/PTC3 (fusion NCOA4 and RET) are by far the most common rearrangements (COSMIC database, 2015). All of the rearrangements are due to DNA damage and result in the fusion of the RET tyrosine kinase domain to the 5′-terminal region of heterologous genes. RET/PTC rearrangements are very common in radiation-induced tumours but have been detected in variable proportions of sporadic (nonradiation associated) papillary carcinomas. Little is known about the clinical and pathologic features of the tumours featuring RET/PTC rearrangements. Several reports have failed to show correlation of RET/PTC rearrangements with clinicopathological markers of increased morbidity (Soares et al., Reference Soares, Fonseca, Wynford-Thomas and Sobrinho-Simões1998; Tallini et al., Reference Tallini, Santoro, Helie, Carlomagno, Salvatore, Chiappetta, Carcangiu and Fusco1998). However, RET/PTC1 and RET/PTC3 have been associated with less and more aggressive tumours, respectively (Nikiforov et al., Reference Nikiforov, Rowland, Bove, Monforte-Munoz and Fagin1997; Tallini et al., Reference Tallini, Santoro, Helie, Carlomagno, Salvatore, Chiappetta, Carcangiu and Fusco1998). A recent study performed on PTC has shown that chromosomal rearrangements including RET fusions are associated with younger age at diagnosis but not with risk of recurrence (Cancer Genome Atlas Research Network, 2014).

Activating somatic mutations in the RET proto-oncogene have been found in sporadic MTC with a frequency ranging from 23 to 69% of patients' tumours. The most frequent somatic mutation is Met918Thr in exon 16 (COSMIC database, 2015). This mutation has been involved in the initial event of the development of MTC and has a poor prognosis (Zedenius et al., Reference Zedenius, Larsson, Bergholm, Bovee, Svensson, Hallengren, Grimelius, Backdahl, Weber and Wallin1995; Romei et al., Reference Romei, Elisei, Pinchera, Ceccherini, Molinaro, Mancusi, Martino, Romeo and Pacini1996). Some other somatic missense point mutations as well as small oligonucleotide deletions or insertions in exons 10, 11, 13 and 15 have also been reported in sporadic MTC tumours but with a considerably lower frequency (Marsh et al., Reference Marsh, Scott, Eng, Learoyd, Capes, Pojer, Richardson, Houghton, Mulligan, Ponder and Robinson1996; Alemi et al., Reference Alemi, Lucas, Sallstrom, Bergholm, Akerstrom and Wilander1997; Kalinin & Frilling, Reference Kalinin and Frilling1998; Uchino et al., Reference Uchino, Noguchi, Yamashita, Sato, Adachi, Yamashita, Watanabe, Ohshima, Mitsuyama, Iwashita and Takahashi1999; Bugalho et al., Reference Bugalho, Coelho and Sobrinho2000).

(iii) RAS

RAS family proteins are small GTPases that play a role in cellular growth, differentiation, adhesion and migration. RAS mutations are among the most common genetic alterations that have been observed in thyroid tumours and that lead to constitutive activation of the RAS proteins. Recent studies have reported that 10–20% of PTC and 40–50% of FTC harbour RAS mutations (Nikiforova et al., Reference Nikiforova, Lynch, Biddinger, Alexander, Dorn, Tallini, Kroll and Nikiforov2003; Nikiforov, Reference Nikiforov2008; Nikiforov & Nikiforova, Reference Nikiforov and Nikiforova2011). They have been associated with higher malignancy, poor prognoses, distant metastasis and shorter overall survival rate in poorly differentiated thyroid carcinomas (Garcia-Rostan et al., Reference Garcia-Rostan, Zhao, Camp, Pollan, Herrero, Pardo, Wu, Carcangiu, Costa and Tallini2003; Volante et al., Reference Volante, Rapa, Gandhi, Bussolati, Giachino, Papotti and Nikiforov2009). RAS mutations have also been reported in MTC (25%) and constitute a frequent molecular event in RET-negative sporadic MTC (Nikiforov & Nikiforova, Reference Nikiforov and Nikiforova2011). However, their role in MTC tumourigenesis remains unclear (Oczko-Wojciechowska et al., Reference Oczko-Wojciechowska, Pfeifer, Rusinek, Pawlaczek, Zebracka-Gala, Kowalska, Kowal, Swierniak, Krajewska, Gawlik, Chmielik, Czarniecka, Szpak-Ulczok and Jarząb2015).

In the Cancer Genome Atlas project result (Cancer Genome Atlas Research Network, 2014), RAS mutations have been identified as driver mutations for PTC and have been significantly associated with highly differentiated tumours enriched for follicular histology and low risk of recurrence.

The RAS genes consist of three families: NRAS, HRAS and KRAS. RAS point mutations mostly occur in codons 12, 13 and 61 (exons 2 and 3) (Lee et al., Reference Lee, Jung, Kim, Bae, Jung, Choi and Kang2013). The NRAS mutation at codon 61 (exon 3) accounted for 67–88% of all RAS mutations (Vasko et al., Reference Vasko, Ferrand, di Cristofaro, Carayon, Henry and DeMicco2003).

(iv) PAX8/PPARγ

PAX8/PPARγ is formed through the translocation t(2;3)(q13;p25) that fuses the promoter and 5′-coding portion of the thyroid-specific transcription factor PAX8 gene to the full-length coding sequence of the nuclear receptor peroxisome proliferator-activated receptor-gamma 1 gene (Kroll et al., Reference Kroll, Sarraf, Pecciarini, Chen, Mueller, Spiegelman and Fletcher2000).

PAX8/PPARγ was presumed to be specific for FTC (Kroll et al., Reference Kroll, Sarraf, Pecciarini, Chen, Mueller, Spiegelman and Fletcher2000). Subsequent studies have confirmed PAX8/PPARγ presence in 30–40% of FTC and also found it in 2–13% of follicular adenomas (Dwight et al., Reference Dwight, Thoppe, Foukakis, Lui, Wallin, Hoog, Frisk, Larsson and Zedenius2003; French et al., Reference French, Alexander, Cibas, Nose, Laguette, Faquin, Garber, Moore, Fletcher, Larsen and Kroll2003; Nikiforova et al., Reference Nikiforova, Lynch, Biddinger, Alexander, Dorn, Tallini, Kroll and Nikiforov2003). Additional studies have reported the occurrence of PAX8/PPARγ rearrangement in the follicular variant of PTC, typically with low frequency (1–5%) and have reported occurrence occasionally in PTC (1·1%) (Armstrong et al., Reference Armstrong, Yang, Yip, Ohori, McCoy, Stang, Hodak, Nikiforova, Carty and Nikiforov2014; Cancer Genome Atlas Research Network, 2014). The clinical course of the PAX8/PPARγ rearrangement has been indolent and the disease free survival was near 100% at 5 years (Yip et al., Reference Yip, Nikiforova, Yoo, McCoy, Stang, Armstrong, Nicholson, Ohori, Coyne, Hodak, Ferris, LeBeau, Nikiforov and Carty2015).

(v) TERT

Telomerase reverse transcriptase (TERT) is a ribonucleoprotein polymerase that maintains telomere repeat TTAGGG at the ends of chromosomes and consists of a protein component with reverse transcriptase activity and a RNA component that serves as a template (Harrington et al., Reference Harrington, McPhail, Mar, Zhou, Oulton, Bass, Arruda and Robinson1997). Recently, highly frequent mutations in the promoter region of TERT have been reported in many malignancies including TC (Horn et al., Reference Horn, Figl, Rachakonda, Fischer, Sucker, Gast, Kadel, Moll, Nagore, Hemminki, Schadendorf and Kumar2013; Huang et al., Reference Huang, Hodis, Xu, Kryukov, Chin and Garraway2013; Killela et al., Reference Killela, Reitman, Jiao, Bettegowda, Agrawal, Diaz, Friedman, Friedman, Gallia, Giovanella, Grollman, He, He, Hruban, Jallo, Mandahl, Meeker, Mertens, Netto, Rasheed, Riggins, Rosenquist, Schiffman, Shih, Theodorescu, Torbenson, Velculescu, Wang, Wentzensen, Wood, Zhang, McLendon, Bigner, Kinzler, Vogelstein, Papadopoulos and Yan2013; Vinagre et al., Reference Vinagre, Almeida, Populo, Batista, Lyra, Pinto, Coelho, Celestino, Prazeres, Lima, Melo, da Rocha, Preto, Castro, Castro, Pardal, Lopes, Santos, Reis, Cameselle-Teijeiro, Sobrinho-Simões, Lima, Máximo and Soares2013). These mutations occur in two hot spot positions, located at -124 bp and -146 bp upstream from the ATG start site and confer enhanced TERT promoter activity putatively by generating a consensus binding site (GGAA) for E-26 transcription factors within the TERT promoter region (Huang et al., Reference Huang, Hodis, Xu, Kryukov, Chin and Garraway2013). In the Cancer Genome Atlas Project results, TERT mutations have been identified in 9·4% of the informative papillary tumours with 7% for C228T, 0·3% for C228A and 2·1% for C250T substitutions (Cancer Genome Atlas Research Network, 2014).

TERT promoter mutations are an indicator of clinically aggressive tumours. In fact, these mutations have been significantly associated with distant metastases, higher stage and persistent disease. Patients with DTC harbouring TERT promoter mutations have been submitted to more radioiodine treatments with higher cumulative dose and to more treatment modalities (Melo et al., Reference Melo, da Rocha, Vinagre, Batista, Peixoto, Tavares, Celestino, Almeida, Salgado, Eloy, Castro, Prazeres, Lima, Amaro, Lobo, Martins, Moura, Cavaco, Leite, Cameselle-Teijeiro, Carrilho, Carvalheiro, Máximo, Sobrinho-Simões and Soares2014). Also, TERT mutations have been correlated with disease specific mortality (Melo et al., Reference Melo, da Rocha, Vinagre, Batista, Peixoto, Tavares, Celestino, Almeida, Salgado, Eloy, Castro, Prazeres, Lima, Amaro, Lobo, Martins, Moura, Cavaco, Leite, Cameselle-Teijeiro, Carrilho, Carvalheiro, Máximo, Sobrinho-Simões and Soares2014). These associations were consistent with the published results of the Cancer Genome Atlas Research Project, where TERT mutations have been associated with older age as well as higher risk of recurrence and it has been suggested that these mutations may be used to identify high risk patients (Cancer Genome Atlas Research Network, 2014). Recently, it has been shown that the prognostic value of TERT mutations is significantly stronger than that of BRAF ^V600E (Muzza et al., Reference Muzza, Colombo, Rossi, Tosi, Cirello, Perrino, De Leo, Magnani, Pignatti, Vigo, Simoni, Bulfamante, Vicentini and Fugazzola2015).

(vi) TP53

Tumour suppressor protein (TP53) is a transcription factor that regulates the expression of target genes in response to diverse cellular stresses, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair or changes in metabolism. Mutations in the TP53 gene are a rare event in well DTC (PTC and FTC), while they are frequent in more advanced forms of carcinoma. In fact, TP53 mutations are a major event in poor DTC and anaplastic TC having a prevalence of 27 and 48%, respectively (Guerra et al., Reference Guerra, Di Crescenzo, Garzi, Cinelli, Carlomagno, Tonacchera, Zeppa and Vitale2013; Pita et al., Reference Pita, Figueiredo, Moura, Leite and Cavaco2014). Virtually, all the mutations that have been reported are located in the hot spot region located between exons 5 and 9, where codon 273 is the one that is more often affected (Donghi et al., Reference Donghi, Longoni, Pilotti, Michieli, Della Porta and Pierotti1993; Fagin et al., Reference Fagin, Matsuo, Karmakar, Chen, Tang and Koeffler1993).